Administration regime for n-hydroxy-4-benzamide

Abstract

N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.

1 - A method of treating a condition selected from carcinoma, tumours, neoplasm, lymphoma, melanoma, glioma, sarcoma, and blastoma in a subject in need thereof, comprising administration of an effective amount of N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide of formula (I): 
       
         
           
           
               
               
           
         
       
       or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in combination with a surgery, chemotherapy, hormone therapy treatment, or radiotherapy. 
     
     
         2 - The method according to  claim 1 , wherein the compound of formula (I), or an addition salt thereof with a pharmaceutically acceptable acid or base, is administered in combination with a chemotherapy, hormone therapy treatment, or radiotherapy. 
     
     
         3 - The method according to  claim 1 , wherein the condition is solid tumours. 
     
     
         4 - The method according to  claim 1 , wherein the condition is breast cancer. 
     
     
         5 - The method according to  claim 1 , wherein the condition is selected from epithelial ovarian carcinoma, fallopian tube carcinoma, and primary peritoneal carcinoma. 
     
     
         6 - The method according to  claim 1 , wherein the chemotherapy treatment is cisplatin, doxorubicin, or pegylated liposomal doxorubicin. 
     
     
         7 - The method according to  claim 1 , wherein the hormone therapy treatment is tamoxifen.